Literature DB >> 4075021

[14C]-beta-phenethylamine, its distribution after administration by various routes to cats, and the effects of monoamine oxidase inhibitors.

G Garcha, P R Imrie, E Marley, D V Thomas.   

Abstract

[14C]-beta-phenethylamine [( 14C]-PEA) was instilled intragastrically, intraduodenally (i.d.) or infused into the portal vein or femoral artery of cats, anaesthetized with chloralose, to investigate its distribution in the body. [14C]-PEA and phenylacetic acid (PAA) accounted for approximately 85% of radioactivity recovered in blood from control cats or those pretreated with deprenyl or mebanazine. Progressively greater portal venous (PV), cranial mesenteric arterial (CMA) and PV-CMA concentrations of PEA and PAA were observed with increase in amount of PEA instilled intraduodenally (i.d.); PAA predominated over PEA, more so in CMA than PV blood. Radioactivity was not recovered from blood following intragastric instillation of PEA. When histamine 1.7 mumol kg-1, i.d., was combined with PEA 1.7 mumol kg-1, i.d., or tyramine 8.5 mumol kg-1, i.d., was combined with PEA 8.5 mumol kg-1, i.d., PV-CMA values for PEA were significantly augmented. Arterial concentrations of PEA were increased 3.5 to 5 fold compared to controls by pretreatment with mebanazine or deprenyl plus clorgyline; arterial concentrations of PAA were reduced. PEA blood concentrations were not significantly altered by clorgyline or deprenyl pretreatment. Infusion of PEA 680, 1020 or 1360 nmol kg-1 min-1 for 20 min into the portal vein raised blood pressure 60 to 100 mmHg (at a PEA concentration of ca, 2 nmol ml-1) but lacked effect on the nictitating membrane despite peak arterial PEA concentrations of 20 nmol ml-1; in cats pretreated with mebanazine or clorgyline plus deprenyl, half-maximum contraction of the nictitating membrane occurred with arterial PEA concentrations of 4.8 to 9 nmol ml-1. In cats pretreated with mebanazine or deprenyl plus clorgyline, half maximum contraction of the nictitating membrane was elicited also by intraduodenal PEA 8.5 mumol kg-1 at arterial PEA concentrations of ca. 2 nmol ml-1, despite lack of effect of PEA 17 mumol kg-1, i.d., in control cats with a peak arterial PEA concentration of 1.8 nmol ml-1. [14C]-PEA and PAA were recovered from liver, kidney, distal small intestine, lung, arterial vessel walls, skeletal muscle, brain, foetus and amniotic liquor, after PEA instilled i.d., overall concentration of PEA exceeding that of PAA except in the kidney. The combined amount of PEA and PAA in kidney was 7 to 20 fold that in other tissues. PEA content of tissues was significantly elevated and that of PAA diminished by pretreatment with deprenyl plus clorgyline, and to a lesser extent after mebanazine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4075021      PMCID: PMC1916635          DOI: 10.1111/j.1476-5381.1985.tb11110.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  18 in total

1.  Evidence for a clorgyline-resistant monoamine metabolizing activity in the rat heart.

Authors:  G A Lyles; B A Callingham
Journal:  J Pharm Pharmacol       Date:  1975-09       Impact factor: 3.765

Review 2.  Another look at the monoamine oxidases and the monoamine oxidase inhibitor drugs.

Authors:  N H Neff; H Y Yang
Journal:  Life Sci       Date:  1974-06-01       Impact factor: 5.037

3.  Beta-phenylethylamine: a specific substrate for type B monoamine oxidase of brain.

Authors:  H Y Yang; N H Neff
Journal:  J Pharmacol Exp Ther       Date:  1973-11       Impact factor: 4.030

4.  A phenylethylamine oxidising defect in migraine.

Authors:  M Sandler; M B Youdim; E Hanington
Journal:  Nature       Date:  1974-07-26       Impact factor: 49.962

5.  Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species.

Authors:  R F Squires
Journal:  Adv Biochem Psychopharmacol       Date:  1972

6.  Metabolism of tyramine-1-14C by the rat.

Authors:  M Tacker; W M McIsaac; P J Creaven
Journal:  Biochem Pharmacol       Date:  1970-10       Impact factor: 5.858

Review 7.  Interactions of monoamine oxidase inhibitors, amines, and foodstuffs.

Authors:  E Marley; B Blackwell
Journal:  Adv Pharmacol Chemother       Date:  1970

8.  Interactions of cheese and of its constituents with monoamine oxidase inhibitors.

Authors:  B Blackwell; E Marley
Journal:  Br J Pharmacol Chemother       Date:  1966-01

9.  Action of sympathomimetic and allied amines on the central nervous system of the chicken.

Authors:  W G Dewhurst; E Marley
Journal:  Br J Pharmacol Chemother       Date:  1965-12

10.  Physiological disposition of beta-phenylethylamine, 2,4,5-trimethoxyphenylethylamine, 2,3,4,5,6-pentamethoxyphenylethylamine and beta-hydroxymescaline in rat brain, liver and plasma.

Authors:  I Cohen; J F Fischer; W H Vogel
Journal:  Psychopharmacologia       Date:  1974-03-21
View more
  2 in total

Review 1.  Individual variation in first-pass metabolism.

Authors:  Y K Tam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

2.  Neuropharmacological and neurochemical properties of N-(2-cyanoethyl)-2-phenylethylamine, a prodrug of 2-phenylethylamine.

Authors:  G B Baker; R T Coutts; T S Rao
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.